Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical.
A study conducted by researchers from University Hospital Augsburg in Germany used Blue Earth's Lu-177-labeled radiohybrid (rh) prostate-specific membrane antigen (Lu-177 rhPSMA-10.1) and its findings were published in December in the Journal of Nuclear Medicine.
The German team reported that of four patients with metastatic prostate cancer who were assessed for radiologic progression-free survival, two had not progressed at 24 and 18 months of follow-up and the other two had progression at 12 and 15 months. The researchers also found that starting prostate-specific antigen levels were reduced by 100%, 99%, 88%, and 35% for the four individual patients.
A phase I and II clinical trial assessing the safety, tolerability, dosimetry, and antitumor activity of Lu-177 rhPSMA-10.1 in eligible men with metastatic castrate-resistant prostate cancer is also underway in the U.S., Blue Earth said.
